NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

iBio, Inc. (IBIO) Stock Analysis

iBio, Inc. (IBIO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

IBIO

$0.84

+$0.02 (+2.31%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IBIO with… →

IBIO Key Statistics

As of Oct 21, 2026
Trading
Open
$0.84
Previous Close
$0.82
Day's Range
0.84–0.88
52-Week Range
0.73–3.82
Volume
517.82K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.26
Valuation
Market Cap
$54.02M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
540.18
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.32
Financials (FY)
Revenue (FY)
$400.00K+77.78%
Net Income (FY)
−$18.38M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
64.31M
1-Year Return
−24.32%
Dividend and dates
Avg Volume
746.38K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, IBIO closed at $0.84, −24.32% over 1 year.

iBio, Inc. (IBIO) has a market capitalization of $54.02M.

In fiscal 2025, IBIO reported revenue of $400.00K.

IBIO Stock Return by Calendar Year

iBio, Inc. (IBIO) 10-year return: what $10,000 became

1 year
$10,000 $7,568
−24.32%
5 years
$10,000 $20
−99.80%
10 years
$10,000 $3
−99.97%

If you had invested $10,000 in iBio, Inc. (IBIO) 10 years ago, at the close on October 21, 2016, it would have been worth $3 at the close on October 21, 2026: −99.97% in total, −55.24% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−56.48%
2025−21.22%
2024+78.83%
2023−84.43%
2022−96.80%
2021−47.62%
2020+320.00%
2019−66.67%
2018−58.33%
2017−55.00%
2016 (partial year)−42.03%

As of October 21, 2026.

IBIO Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$400.00K−$18.38M−4,594.3%
2024$225.00K−$24.91M−11,069.8%
2023$0.00−$65.01M—
2022$1.88M−$50.39M−2,674.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$400.00K—−$18.60M−$18.38M−4,594.3%
2024$225.00K—−$16.63M−$24.91M−11,069.8%
2023$0.00—−$29.34M−$65.01M—
2022$1.88M$2.17M−$29.70M−$50.39M−2,674.7%

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

IBIO Valuation vs Biotechnology Median

Median of 608 stocks
MetricIBIOBiotechnology medianvs median
P/S ratio540.1813.3040.6x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

iBio, Inc. (IBIO) is capitalised at $54.02M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 23.

The 52-week range on file runs from $0.73 to $3.82. IBIO last closed at $0.84 on October 21, 2026. That is +$0.02 (+2.31%) against the previous close. The latest close sits 15.07% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $400.00K. Against the prior fiscal year total of $225.00K, that is a change of +77.78%. The same year closed with a net loss of $18.38M. Earnings per share on a trailing basis come to −0.32.

Across the 4 fiscal years on file, revenue moves from $1.88M in 2022 to $400.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 540.18. On price-to-sales that is 40.6 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is −24.32%. Measured over 10 years, that is −55.24% a year compounded. Beta against the wider market is reported at 1.26. Daily returns over the trailing 10 years annualize to a volatility of 157.37%.

Growth & Income

No dividend is on file for IBIO.

Across the complete calendar years on file, 2020 returned +320.00% and 2022 returned −96.80%. Of the 9 complete calendar years on file, 2 finished higher. 2026 is still running; the total return is −56.48% year to date.

Peer Comparison

iBio, Inc. (IBIO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
iBio, Inc. IBIO $54.02M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. iBio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About iBio, Inc.

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies. In addition, the company is developing, an antibody therapeutics to treat glioblastoma and other cancers by selectively killing EGFRvIII tumor cells without destroying healthy tissue; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2–expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Visit website →